Jeff Hackman approved as the new CEO of Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc shared a post on LinkedIn:

”Today we announced the appointment of Jeff Hackman, an accomplished industry leader with extensive commercialization and oncology expertise, as our new Chief Executive Officer (CEO) and a member of the Board of Directors. Jeff will guide Fennec’s strategic direction for operational success in the expansion of PEDMARK use in community oncology and the adolescent and young adult (AYA) population.

We extend our gratitude to Rosty Raykov, Fennec’s CEO since 2009, for his leadership and commitment in bringing a much-needed therapy to the oncology population at risk of irreversible hearing loss, and look forward to his continued work as an active member of our Board.”

Source: Fennec Pharmaceuticals Inc/LinkedIn

Jeff Hackman is the Chairman and CEO of Comera Life Sciences and Fennec Pharmaceuticals. Previously he was the President of EUSA Pharmaceuticals, North America. He was also the Interim CEO and Chief Operating Officer at Novelion Therapeutics. He has also been Senior Vice President, Head of US Oncology and GI at Shire.